Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT

Retrospective Collection of Data on Patient With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Y90 Ibritumomab Tiuxetan Radioimmunotherapy Plus High-Dose Chemotherapy and Autologous Stem Cell Transplant

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02992223

Enrollment

Registered

2016-12-14

Start date

2014-07-31

Completion date

2015-07-31

Last updated

2016-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma

Keywords

Aggressive B-cell non-Hodgkin Lymphoma, Relapsed, Refractory, Zevalin, Y90 Ibritumomab Tiuxetan, Autologous stem cell transplant, BEAM, Recurrent

Brief summary

Evaluate if Y90 Ibritumomab Tiuxetan Radioimmunotherapy in addition to standard high dose chemotherapy followed by autologous stem cell transplant could improve prognosis in patients affected by relapsed/refractory aggressive non Hodgkin lymphoma

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* High Risk Relapsed/refractory aggressive non-hodgkin lymphoma defined as: * Progressive disease * Early relapse (within 12 months from response) * Recurrent relapse * Treated with salvage chemotherapy followed by Y90 Ibritumomab Tiuxetan plus high-dose chemotherapy and Autologous stem cell transplant * Age \> 18 years * Previous treatment with Rituximab * Written informed consent

Exclusion criteria

* Patient with no complete data available for collection

Design outcomes

Primary

Measure	Time frame	Description
Overall Survival	Date of last follow-up for at least 18 months (up to 78 months)	Time to last follow-up or death
Progression Free Survival	From first response to last follow-up for at least 18 month (up to 78 months)	Time from last response to nearest relapse or follow-up

Outcome results